These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33367923)

  • 1. Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab.
    Asano R; Shinoda K; Tsuda R; Hounoki H; Kawataka M; Makino T; Imura J; Hamaguchi Y; Tobe K
    Rheumatology (Oxford); 2021 Jun; 60(6):e197-e199. PubMed ID: 33367923
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
    Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
    Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
    Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
    Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
    Messer A; Drozd B; Glitza IC; Lu H; Patel AB
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint Inhibitors May Cause Pseudoprogression and Dose-Limiting Side Effects.
    Wiley K
    ONS Connect; 2016 Jul; 31(7):24. PubMed ID: 30549937
    [No Abstract]   [Full Text] [Related]  

  • 6. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.
    Liu P; Pan X; Chen C; Niu T; Shuai X; Wang J; Chen X; Liu J; Guo Y; Xie L; Wu Y; Liu Y; Liu T
    Blood; 2020 Mar; 135(11):826-833. PubMed ID: 31914172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate.
    Eze C; Manapov F; Gratzke C; Schmidt-Hegemann NS; Jung A; Kirchner T; Heinemann V; Stief CG; Belka C; Boeck S
    Eur J Cancer; 2018 May; 95():109-111. PubMed ID: 29477368
    [No Abstract]   [Full Text] [Related]  

  • 8. Perioperative Nivolumab in Resectable Lung Cancer. Reply.
    Cascone T; Spicer JD; Provencio Pulla M
    N Engl J Med; 2024 Aug; 391(6):573-574. PubMed ID: 39115074
    [No Abstract]   [Full Text] [Related]  

  • 9. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
    Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexisting TIF1γ-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1γ Antibody-positive Dermatomyositis.
    Nakanishi Y; Yamaguchi K; Yoshida Y; Sakamoto S; Horimasu Y; Masuda T; Nakashima T; Miyamoto S; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
    Intern Med; 2020 Oct; 59(20):2553-2558. PubMed ID: 32581161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
    Zamarin D; Burger RA; Sill MW; Powell DJ; Lankes HA; Feldman MD; Zivanovic O; Gunderson C; Ko E; Mathews C; Sharma S; Hagemann AR; Khleif S; Aghajanian C
    J Clin Oncol; 2020 Jun; 38(16):1814-1823. PubMed ID: 32275468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.
    Ceccarelli F; Botticelli A; Natalucci F; Olivieri G; Cirillo A; Alessandri C; Marchetti P; Conti F
    Clin Transl Oncol; 2021 Sep; 23(9):1961-1962. PubMed ID: 33728870
    [No Abstract]   [Full Text] [Related]  

  • 13. An update on the safety of nivolumab for the treatment of advanced melanoma.
    Czarnecka AM; Rutkowski P
    Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis.
    Ferrian S; Liu CC; McCaffrey EF; Kumar R; Nowicki TS; Dawson DW; Baranski A; Glaspy JA; Ribas A; Bendall SC; Angelo M
    Cell Rep Med; 2021 Oct; 2(10):100419. PubMed ID: 34755133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related myositis resulting from combination therapy of ipilimumab and nivolumab in patient with metastatic renal cell carcinoma.
    Okubo N; Kijima T; Nukui A; Kamai T
    BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32912886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
    Miyauchi M; Toyoda M; Zhang J; Hamada N; Yamawaki T; Tanaka J; Harada K; Kashizaki F; Fukagawa M
    J Diabetes Investig; 2020 May; 11(3):748-749. PubMed ID: 31587459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
    Kosche C; Stout M; Sosman J; Lukas RV; Choi JN
    Melanoma Res; 2020 Jun; 30(3):313-316. PubMed ID: 31567590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
    Kotobuki Y; Tonomura K; Fujimoto M
    Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genital lichen sclerosus after nivolumab.
    Miraglia E; Soda G; Giustini S
    Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.